Wockhardt becomes the first domestic Indian drug maker to secure an exclusive marketing right as the government grants an EMR for its topical anti-bacterial drug Nadoxin.
Once again, Brazil's government is playing hardball in its efforts to get deep discounts on anti-HIV drugs.
A Chinese court rejects a bid by Johnson & Johnson to nullify a registered trademark that could easily be confused with the company's Carefree line of sanitary towels.
India’s government introduced its patent bill ahead of schedule, seeking to bring the country into compliance with its international obligations regarding intellectual property rights by 2005.
Supreme Court sustains cancer-therapy patent in suit versus Hoffman-La Roche, but asks European Court of Justice to rule on cross-border enforcement of patents.
Indian drug companies are lobbying the government for an exemption from patent infringement provisions in amendments to the country’s patent law for drugs already in the market.
University sues Micro Therapeutics and Dendron over patents related to the treatment of brain aneurisms.
Genentech takes licenses for Xolair, Raptiva and Avastin under final settlement agreement.
Government approves introduction of bills aimed at securing TRIPS compliance and stiffen penalties for drug counterfeiting.
In a case likely to have far-reaching implications for settlements of patent litigation in the pharmaceutical industry, the FTC says three drug makers colluded to keep a generic off the market.
Court rules two products by Boston Scientific infringe a patent by Medinol, but imposes minimal restrictions on sales.
Lawsuits resulting from Barr's Abbreviated New Drug Application for a generic version of hyperactivity drug Adderall XR have been consolidated.
The European Parliament adopts sweeping new legislation aimed at standardizing regulatory data protection for drugs across the European Union.
Another setback for Cellergy, which was forced to pull its NDA for the treatment last year and was sued over a licensing agreement last week.
The U.S. District Court for the Southern District of New York again extended the restraining order to prevent Eon Labs from introducing Bupropion, the generic equivalent of GlaxoSmithKline’s antidepressant Wellbutrin.
Courts in Europe and the U.S. dealt further setbacks for AstraZeneca’s efforts to extend patent rights to an ulcer treatment that was once the world’s best-selling drug.
University claims AMDL induced researcher to sell combination immunogene therapy technology in violation of patent policy.
Irish drug maker says move follows termination of an agreement with Pfizer to jointly develop research into treating Alzheimer's disease.
Even as Pennie & Edmonds is shutting down, Pfizer and the University of Rochester are taking the firm to court over alleged ethical breaches next week.
Out-of-court settlement yields licensing agreements with several local drug makers.